imaging – Page 2 – Penn Bioengineering Blog

June 19, 2018June 19, 2018

Week in BioE (June 19, 2018)

Dolphin Echolocation Could Improve Ultrasound

Dolphins are among the most intelligent creatures on earth, showing behaviors such as teaching, learning, cooperation, delayed gratification, and other markers of high intelligence. Dolphins communicate vocally with one another, although we aren’t sure exactly what they communicate. While this communication isn’t “language” as humans define it, it uses echolocation — finding objects and orienteering on the basis of reflected sound — which humans don’t use in their communications.

Now, we have new information about dolphin echolocation thanks to an article recently published in the Journal of the Acoustical Society of America by mathematicians and biomedical engineers in Sweden. On the basis of earlier research finding that dolphin echolocation signals consist of two tones, rather than one, the new study finds that these two tones are emitted at slightly different times and that the sound waves have a Gaussian shape, similar to a bell curve. Using a mathematical algorithm, the authors successfully simulated echolocation signals in the lab.

The findings explain how dolphins use echolocation effectively but could also contribute to more accurate sound-based diagnostic techniques — particularly ultrasound, which relies heavily on methods similar to echolocation to provide images of moving tissues within the body, e.g., prenatal imaging and heart contraction.

Modeling Diseased Blood Vessels for Drug and Device Testing

Drugs and devices require extensive testing before they are approved by regulatory agencies and used to treat human patients. Tissue engineering has helped bridge the gap between a promising idea and its use in a patient by creating technologies that mimic the complex structure of human tissue. Most of these technologies focus on the engineering of healthy tissues and much less on constructing models of diseased tissue. These models of diseased tissue may be useful for designing treatments for diseases and understanding how diseases are caused.

In this light, Marsha W. Rolle, PhD, Associate Professor of Biomedical Engineering at Worcester Polytechnic Institute (WPI), is working to create engineered blood vessels that are already diseased as a way to test possible treatments. With three years of funding from the National Institutes of Health’s National Heart Lung and Blood Institute amounting to nearly $500,000, Dr. Rolle and her research team create these damaged vessels by engineering smooth muscle cells to form tubes 2 mm in diameter. These synthetic vessels are then modified to resemble features of diseases. For example, growth factors attached to microspheres can encourage the growth of tissue in small parts of the vessel wall, eventually becoming areas of narrowing in the vessel. Similarly, other factors could lead to changes in the vessel that resemble aneurysms. In both cases, the function of the microengineered vessel could be measured as the change happens, providing insight into either vascular stenosis or aneurysms, neither of which is possible in humans.

Dr. Rolle’s first step will be to test the damaged engineered vessels with existing medications. If successful, this new technique could be used for testing of new drugs and devices prior to testing in animals.

New Heart Implant Can Deliver Drug

Speaking of damage to the circulatory system, a new article in Nature Biomedical Engineering details how engineers at MIT, Harvard, and Trinity College, Dublin, created a heart implant that can deliver targeted therapy to damaged heart tissue. The authors, led in part by Conor J. Walsh, PhD, and David J. Mooney, PhD, of Harvard, created a device called Therepi, approximately 4 mm in size, which is deployed with a hypodermic. Once placed, a reservoir of medicine within the Therepi treats the damaged heart muscle. In addition, it can be refilled without needing to remove the implant. The Nature Biomedical Engineering study is limited to testing in rats, but the authors see testing in humans in the near future.

Erdős-Rényi Prize for Penn Professor

Danielle S. Bassett, PhD, Eduardo D. Glandt Faculty Fellow and Associate Professor of Bioengineering at the University of Pennsylvania, has been named the 2018 recipient of the Erdős-Rényi Prize in Network Science by the Network Science Society (NetSci). NetSci has recognized Dr. Bassett for “fundamental contributions to our understanding of the network architecture of the human brain, its evolution over learning and development, and its alteration in neurological disease.” Dr. Bassett will receive the award and deliver a lecture on June 14 at the International Conference on Network Science in Paris. She is the seventh scientist and fourth American to receive the prize.

The Erdős-Rényi Prize is awarded annually to a scientist younger than 40 years old for his/her achievements in the field of network science. It is named for the Hungarian mathematicians Paul Erdős, whose surname provided a measurement for research collaboration by academic mathematicians, and Alfréd Rényi, whose work focused on probability and graph theory. In network science, an Erdős-Rényi model is a model for generating random graphs. Dr. Bassett’s research applies the principles of network science in neuroscience, with the intention of understanding the brain better by modeling the networks and circuits of our most complex organ.

People and Places

Two new centers dedicated to health sciences are opening. Western New England University opened its new Center for Global Health Engineering in April, with Michael J. Rust, PhD, Associate Professor of Biomedical Engineering, as the codirector under director Christian Salmon, PhD. Elsewhere, Northwestern University launched a new center — the Center for Advanced Regenerative Engineering — with Guillermo Ameer, PhD, Daniel Hale Williams Professor of Biomedical Engineering and Surgery at Northwestern, as founding director.

Finally, Joseph J. Pancrazio, Ph.D., Professor of Bioengineering at the University of Texas at Dallas and Associate Provost, has been named Vice President for Research. Before moving to UT Dallas in 2015, Dr. Pancrazio was the founding chair of Bioengineering at George Mason University in Virginia.

April 24, 2018April 24, 2018

Week in BioE (April 24, 2018)

Pushing the Limits of Imaging

7T-MRI — An image showing 7-tesla MRI of the human brain

Since the late 1970s with the advent of computed tomography (CT), medical imaging has grown exponentially. Magnetic resonance imaging (MRI) offers some of the clearest pictures of human anatomy and pathology, particularly as the strength of the magnetic field used (measured in units called Teslas) increases. However, MRI machines are expensive, and the costs increase as one uses a machine with higher field strength to ‘see’ the human more closely. Therefore, it is often more useful (and certainly less expensive) to modify existing MRI technology on hand, rather than acquire a new machine.

A recent example is the work of Tamer Ibrahim, PhD, Associate Professor of Bioengineering at the University of Pittsburgh. Dr. Ibrahim used a series of multiple NIH grants to develop a coil system for Pitt’s 7T-MRI — one of only approximately 60 worldwide — enabling it to more accurately image the brain’s white matter. Dr. Ibrahim is interested in seeing how hyperintensity in the white matter is related to depression, which is one of the highest-burden but least-discussed diseases in the world. Called a “tic-tac-toe” radiofrequency coil setting, the device that Dr. Ibrahim created is a network of antennas fitted to the head that minimize concerns such as coil heating and radiofrequency intensity losses, as well as safety concerns.

Dr. Ibrahim has more NIH funding on the way to continue optimizing his device and apply it in other psychiatric and neurological disorders. Rather than purchasing a new MRI machine with higher field strengths to achieve this image quality, Dr. Ibrahim’s coil design can be used on existing machines. One possible outcome is more clinicians using this new coil to study how changes in the brain’s white matter structure occur in a broad range of brain diseases, leading to both earlier detection anfor ad more effective treatment.

Smart Shunt for Hydrocephalus

Hydrocephalus, once more commonly known as “water on the brain,” is a condition marked by abnormal accumulation of cerebrospinal fluid (CSF) in the skull. If unchecked, the accumulation of fluid will create dangerous pressures in the brain that can result in brain damage. Hydrocephalus occurs in one in every 1,000 births, and nearly 400,000 adults in the US suffered at least on episode of hydrocephalus. For both infants and adults, hydrocephalus is often treated surgically with the installation of a shunt to channel the excess CSF out of the cranium. These shunts are simple but effective devices that operate mechanically. However, since they’re entirely mechanical, they fail over time. Being able to determine that such a failure was imminent could allow patients to receive a replacement shunt before complications arise.

To meet this clinical need, a group of scientists at the University of Southern California (USC) updated existing shunt systems with microsensing technology, creating a “smart shunt” that can tell clinicians how an installed shunt is functioning and alert the clinician that a replacement is needed. The group, including Ellis Fan-Chuin Meng, PhD, Gabilan Distinguished Professorship in Science and Engineering, Dwight C. and Hildagarde E. Baum Chair, and Professor of Biomedical Engineering and Electrical Engineering-Electrophysics, has created a start-up called Senseer to produce these smart shunts.

The shunt currently measures pressure, flow, and occlusion using miniature microelectronics sensors. If device approval comes, the company hopes to move on to developing smart sensors for other organ systems.

DNA-based Drug Testing

Drug and alcohol testing is a controversial topic, partly because of the balance between individual rights to use legal drugs and potential for societal harm if these drugs are abused or if patients transition into illegal drug use and dependence. Inventing technology to determine when, and how much, a person has been drinking or using drugs (including tobacco) would probably increase, rather than decrease, the controversy involved in the topic.

New technology reported recently adds a new element to this discussion. According to Robert Philibert, MD, PhD, Professor of Psychiatry at the University of Iowa and an adjunct faculty member in the Department of Biomedical Engineering, his company’s tests, which rely on epigenetic markers of substance use, could be used, for example, to inform a primary care physician about the actual history of substance use, rather than relying solely on patients’ self-reported use.

Dr. Philibert’s tests are currently pending approval by the Food and Drug Administration. Marketing for the products will begin in the coming weeks.

People and Places

Recognizing the changing priorities in engineering and the growing role of data sciences, Boston University has decided to adapt its curriculum by adding data science requirements for all majors. According to John White, PhD, Chair of the Department of Biomedical Engineering, “Advances in data sciences and computing technology will allow us to make sense of all these data.”

The Biomedical Science Program at Howard Payne University in Brownwood, Texas, has received a $200,000 grant from the James A. “Buddy” Davidson Charitable Foundation to endow a scholarship in Davidson’s name, as well as to refurbish the program’s Winebrenner Memorial Hall of Science.

Finally, we offer our congratulations this week to James C. Gee, PhD, Professor of Radiologic Science in Radiology at the University of Pennsylvania’s Perelman School of Medicine and a Graduate Group faculty member in Penn’s Department of Bioengineering. Dr. Gee was named a fellow of the American Institute for Medical and Biological Engineering.

October 23, 2017October 20, 2017

Oncology/Engineering Review Published

Michael Mitchell, Ph.D., who will arrive in the Spring 2018 semester as assistant professor in the Department of Bioengineering, is the first author on a new review published in Nature Reviews Cancer on the topic of engineering and the physical sciences and their contributions to oncology. The review was authored with Rakesh K. Jain, Ph.D., who is Andrew Werk Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School, and Robert Langer, Sc.D., who is Institute Professor in Chemical Engineering at the David H. Koch Institute for Integrative Cancer Research at MIT. Dr. Mitchell is currently in his final semester as a postdoctoral fellow at the Koch Institute and is a member of Dr. Langer’s lab at MIT.

The review focuses on four key areas of development for oncology in recent years: the physical microenvironment of the tumor; technological advances in drug delivery; cellular and molecular imaging; and microfluidics and microfabrication. Asked about the review, Dr. Mitchell said, “We’ve seen exponential growth at the interface of engineering and physical sciences over the last decade, specifically through these advances. These novel tools and technologies have not only advanced our fundamental understanding of the basic biology of cancer but also have accelerated the discovery and translation of new cancer therapeutics.”

October 2, 2017October 6, 2017

Week in BioE (October 6, 2017)

We Bleed Green

field goal Biomechanics is a subdiscipline within bioengineering with many applications that include studying how tissue forms and grows during development (see our profile of incoming faculty member Alex Hughes to learn more) and determining how the ‘imprint’ of spine-based pain can be treated with anti-inflammatory medication (see story here on work from the lab of Dr. Beth Winkelstein). Understanding and analyzing human performance are other areas of biomechanics application. On September 24, Eagles kicker Jake Elliott set a team record when he kicked a 61 yard field goal at the end of regulation time to beat the Giants. Marking the achievement, the Philadelphia Inquirer featured an interview with Dr. Chase Pfeifer, a biomedical engineer from the University of Nebraska-Lincoln (UNL), to find out what factors contribute to a successful field goal from this distance. Pfeifer has both knowledge and experience with this question; he was a backup kicker for the Florida State Seminoles as an undergraduate. In the Inquirer, Dr. Pfeifer explained to readers the biophysics behind Elliott’s record kick.

Dr. Pfeifer assures readers that there’s more to kicking a 61-yard field goal than strong muscles. He explains, “The timing of muscle activation was actually more important than muscle strength in achieving that higher foot velocity.” Four muscle groups were activated by Elliott to set his record. In addition, Pfeifer’s colleague at UNL, Professor Tim Gay of the physics department, explained to the Inquirer how the climatic conditions favored Elliott’s success. Specifically, since it was a hot day, the air was less dense, allowing for longer kick distances.

Speaking of football, a new article in Annals of Biomedical Engineering offers some hope for NFL players and the league itself in the wake of growing awareness and concern about chronic traumatic encephalopathy (CTE). The increased focus on CTE has resulted in increased research on the condition and its prevention. Real-time measurement of impact energy in head injuries has, until now, relied on measurements of the motion of the head or helmet, rather than measuring the impact energy directly.

In the Annals article, scientists from Brigham Young University, including David T. Fullwood, Ph.D., professor of mechanical engineering, report on the testing of a new sensor used to measure the impact event. The authors implanted nano-composite foam (NCF) sensors into football helmets and then submitted the helmets to two dozen drop tests. The data collected from the foam sensors were compared to two of the most widely used indices to measure head injury risk, achieving excellent correlation (>90%) with injury risk indicators. The authors intend to test newer models of the sensors in the future, as well as in vivo testing.

Breast Cancer News

Despite significant advances in diagnosis and treatment, breast cancer remains the most common cancer in women. More than 300,000 women are newly diagnosed in the United States each year. Maximizing the effectiveness of treatment involves early detection of the tumor and its metastasis. Imaging plays a key role in this process. However, early tumors are very small, making their detection quite difficult.

In response to this challenge, Zheng-Rong Lu, Ph.D., the M. Frank Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering at Case Western Reserve University, has coauthored a paper recently published in Nature Communications showing that a newly developed type of molecule could be used for highly sensitive magnetic resonance imaging (MRI) to detect and stratify early breast tumors.

Dr. Lu and his colleagues engineered molecules called fullerenes, which are hollow, spherical molecules of carbon. The team embedded gadolinium, a rare earth metal that is easily detected with MR imaging, into the fullerene to create metallofullerenes. They tested these metallofullerenes both in vitro and in a mouse model to determine how well they enhanced the ability of MRI to detect tumors. Metallofullerene particles could not only distinguish cancers more effectively on MRI, but they could also distinguish more aggressive tumor types from less aggressive ones. In addition, they found that metallofullerenes rapidly cleared from the body via the kidneys, ensuring that these agents would pose minimal toxicity risk. If this technology proves effective in humans, it could significantly improve the early detection of breast cancer and, in turn, survival rates.

One possible risk for breast cancer patients is the metastasis of the cancer to other body regions. Scientists at Cornell identified a mineral process underlying breast cancer metastasis to bones, reporting their findings in PNAS. Led by Claudia Fischbach-Teschl, Ph.D., associate professor of biomedical engineering at Cornell, the authors investigated how hydroxylapatite — a naturally occurring mineral — participates in metastasis.

Dr. Fischbach-Teschl and her colleagues used X-ray scattering and Raman spectroscopy to examine the nanostructures of hydroxylapatite in the bones of mice with and without breast cancer. They found that bones were more likely to be metastasized by primary breast tumors if the hydroxylapatite crystals in them were less mature. Before the cancer spreads to the bone, the authors found that the cancer “communicates” with these immature crystals, preparing sites in the bone to which the cancer can spread.

With 80% of metastatic breast cancer cases spreading to the bones, the discovery of the Cornell team could contribute enormously to preventing metastasis — not only of breast cancer but also of any cancer with a greater likelihood of spreading to the bones.

A Review of Glucose Monitoring Technology

Our ability to treat diabetes has consistently improved over the years, but the need for patients with the disease to monitor their blood glucose requires either multiple needle pricks or invasive insulin pumps. However, several technologies are in development around the world to make blood glucose monitoring less cumbersome. In a new article published in Bioengineering, engineers in the United Arab Emirates offer a review of the latest technologies, including analytic methods that could streamline decisions on doses of insulin to offset high glucose levels.

People and Places

The University of California, Davis, opened its Molecular Prototyping and BioInnovation Laboratory (MPBIL) in 2014. Since then, the “biomaker lab” has stood as an example of the future of biotechnology education. In collaboration with UCD’s First-Year Seminar Program, the MPBIL has launched a student-designed pilot course that has thus far yielded three seminars. You can read more about UCD’s innovative program at their Web site.

To promote diversity in engineering, the cosmetics company L’Oréal started the L’Oréal USA For Women in Science Program, which awards Changing the Face of STEM mentoring grants. Among this year’s recipients is John Hopkins University’s Sridevi Sarma, Ph.D. Dr. Sarma, who is an associate professor of biomedical engineering, will use her grant in collaboration with the Girls Scouts of Central Maryland to promote physics education for young women. Congratulations to her!

July 26, 2017July 26, 2017

Burdick Recognized by NIH in Two Programs

Jason Burdick, Ph.D., professor in the Department of Bioengineering, was among the recent recipients of a grant from Sharing Partnership for Innovative Research in Translation (SPIRiT), a pilot grant program awarded by the Clinical and Translational Science Award (CTSA) division of the National Institutes of Health (NIH).

Dr. Burdick’s research, undertaken with Albert Sinusas, MD, of Yale, concerns the development of a noninvasive treatment to limit the damage to the heart caused by heart attacks, which are suffered annually by almost 750,000 Americans. Using single-photo emission computed tomography (SPECT), the technique identifies the damaged heart muscle on the basis of enzymes activated by damage, followed by the targeted administration of bioengineered hydrogels for the delivery of therapeutics

Dr. Burdick says, “This research has the potential to advance treatments for the many individuals with heart attacks who have few current options. Our approach uses injectable materials and advanced imaging techniques to address the changes in protease levels after heart attacks that can lead to tissue damage.”

In other news, Dr. Burdick was one of 12 researchers named by the NIH’s Center for Engineering Complex Tissues to lead collaborative projects aimed at generating complex tissues for several parts of the body.

June 16, 2017June 19, 2017

Researchers Visualize Resistant Cancer Cells

by Meagan Ita, Ph.D. Student in Bioengineering and GABE Co-President

Cancer is a disease that affects millions, and over the last several decades, researchers have delved deeply into the biological underpinnings of the disease in the hopes of finding a cure. One major discovery is that mistakes in your DNA “instructions” can lead to cancer by crossing the wires in your cellular circuitry, and researchers have developed amazing new drugs that can cause tumors to melt away by targeting these broken components. The problem though is that, most of the time, the tumors come back, and this is a huge barrier to cures.

Shaffer ASCO — Picture of patient treated with vemurafenib and then developing resistance. Courtesy of the American Society of Clinical Oncology

For a long time, everyone assumed that the reason the tumors came back was DNA mistakes on top of the original mistakes, with these new mistakes blocking the activity of the anti-cancer drug. However, new work led by Sydney Shaffer from the Arjun Raj Lab at Penn Bioengineering, published this week in Nature, challenges this view by looking all the way down at individual cancer cells and seeing how they respond to these drugs on a cell-by-cell basis.

Sydney found that in melanoma, contrary to what researchers thought, it need not be a DNA mistake that leads a cell to become resistant to the drug, but rather a change in cellular identity. Just like your body has cells of all different types, like skin cells and brain cells, cancer cells appear to change between different types, but unlike in the body, cancer cells do it in a seemingly random and uncontrolled way, and the cells exploit this variability to allow those rare cells that have changed their type to survive the drug.

Here, we talk with Sydney about the inspiration, triumphs, and challenges she faced in her research.

What was the initial inspiration for looking at drug resistance in melanoma?

For the first two years of working on this project, we actually didn’t have a clear question in mind. I was just trying a bunch of different experiments with melanoma cells, and I noticed something that we found thought-provoking. Whenever we gave the melanoma cells a particular drug, they would become resistant at exactly the same point in time. At first, this may not seem unusual, but for example, if everyone showed up at a restaurant to eat lunch at exactly noon, you would guess this was not happening purely by chance. Maybe classes let out right beforehand? Or a big meeting? For the melanoma cells, we would similarly expect there to be a range of different times for the cells to become resistant, but instead it all happened at once.

This observation helped us figure out that the drug-resistant cells probably already exist before we treat them. It also got us curious about the particular processes that make the cells resistant, and we spent many lab meetings discussing this observation until one postdoc, Gautham Nair, suggested trying some experiments based upon the classical molecular biology experiments of Luria and Delbrück.

Who were Luria and Delbrück, and how did they influence your work?

Max Delbrück and Salvador Luria (below) were scientists who, in the 1940s, performed a clever experiment that demonstrated that bacteria become resistant to viruses through random DNA mutations. According to Wikipedia, Luria actually had the idea for these experiments while watching slot machines!

Shaffer D&L — Delbrück (left) and Luria. Courtesy of the Genetics Society of America.

Their experiment was super simple: it was basically a statistical way to see whether cells “sense and respond” to a challenge, or whether they just passively get a mutation that lets some fraction of them survive the challenge, basically like Darwinian evolution. The idea is that, in the first scenario, there is no history: every cell has an equal chance to respond when challenged.

But in the second scenario, history matters in that if your great-grandparent was a survivor, then all your relatives would be too. If you could redo history over and over, then sometimes maybe your great-great-great-great-grandparent would be a survivor, and so you would get a whole bunch of survivors when the challenge came. Luria and Delbrück’s results showed that this second scenario was what happened with bacteria, providing the first evidence for genetic mutations in bacteria occurring in the absence of selection, and they both went on to win a Nobel prize in 1969.

Arjun actually had just lectured about these experiments in our graduate course on modeling biological systems. We adapted the same strategy and theory as Luria and Delbrück’s experiments for our work but applied it to melanoma and actually found a different result. Our experiments showed that resistance in melanoma does not arise through a heritable DNA mutation.

Shaffer colony — Picture of a resistant colony growing in the Raj lab.

Based upon this work, do you have any ideas for how we might prevent resistance in patients?

Yes. The recommended dosing for many of these drugs is daily. Our work would suggest that something like interval therapy might be more effective, for instance, if you gave the drug for a few days, killed many of the tumor cells, and then stopped the drug. During the time that the drug is stopped, the cells that initially survived the drug (we call these cells pre-resistant) could then transition out of this cell state and back to a sensitive state. Then, when the patient takes the drug again, it would be more effective at killing the remaining tumor cells. Another idea would be to find drugs that are specific to the pre-resistant cells and give these drugs in combination with other targeted therapies.

Were there any “Aha!” moments while working on this project?

One of the most exciting moments of this research was when we first found the pre-resistant cells. Hidden among thousands of pictures of empty cells, we were shocked to actually see the rare cells full of brightly tagged resistance genes (below).

Shaffer cells — Resistant cells growing in the Raj lab.

What were some low points in working on the project? Do you recall any specific moments that you just felt intellectually and/or emotionally stumped? How did you get through them?

Oh yes, there were definitely low points during this project. One that stands out to me specifically was this one Friday afternoon where I presented at lab meeting. At the time, I only had a little bit of preliminary data. One of the members of the lab asked me a series of questions about resistance: How many different drug doses had I tried? Could I just give a lot and kill them all? What dose of drug is relevant for patients? What about drug resistance? Was I really interested in? All reasonable questions to ask. However, this was really overwhelming to a first-year graduate student because it made me realize that I didn’t have a clearly defined project that I was working on yet. There were just so many different questions that I didn’t know where to start.

Ultimately, with Arjun’s guidance, I came to realize that this was part of the process of figuring out what my thesis project would be, and the vagueness of our ideas at this time was a great thing because it left me open to find a problem that I found really interesting.

At another point in working on this: I remember that we were clearly conceptually stuck. We had identified the rare cells, but it wasn’t clear how to find out if these were the same cells that become resistant to drug. I had an entire lab meeting where we discussed this concern and came to the conclusion that, without some connection between the cells in this state and resistance, the work would be very speculative, which felt unsatisfying to me. Unfortunately, there wasn’t a quick fix to this problem. We just ended up trying a whole bunch of different ideas and eventually one of our strategies worked out.

Were there any funny moments that stand out to you?

Yeah! I was 40 weeks pregnant as we were finishing off our first submission of the paper! As my due date passed, I was really feeling the pressure to finish everything. Each day, I was coming into lab and just hoping I wouldn’t go into labor yet! Actually, the members of our lab had placed bets on when the baby would be born. Fortunately, those who bet on a late arrival ended up winning, and we submitted the paper the day before my daughter, Julien, was born. I was actually still at the hospital when I got the e-mail that the paper went to review.

So even though it might seem like this project is checked off the list with a kick-ass publication, there are probably a bunch of unfinished ideas you have. So,what are you working on next? Will this project ever be “done?”

For sure. The list of unfinished ideas is very long, and some of the questions that came from this work are now being pursued by other people in the lab. Right now, I’m working on ways of measuring the length of time that individual cells remain in these different cell states.

Interested in sharing your research in Penn BE? Contact penngabe@gmail.com for an interview by GABE (Graduate Association of Bioengineers) and let us know!

May 17, 2017May 17, 2017

Project Builds on Breast Cancer Screening Tech

Breast cancer continues to affect more than 10% of all women — and a small percentage of men — despite significant advances in diagnosis and treatment. While a majority cases today can be successfully treated, early detection is essential to beginning treatment before it’s too late.

Among the more recent innovations in screening has been three-dimensional mammography. However, this modality has lacked the ability to personalize the scan to the individual patient’s breast, instead only acquiring several two-dimensional images along the chest wall, resulting in a lack of individualization for the patient.

A senior design project team at the University of Pennsylvania’s Department of Bioengineering, however, has helped to develop a more personalized 3D imaging technology, which acquires a series of images but instead following the contour of the breast itself. With their efforts, the team earned one of the three awards given to student teams yearly.

The four-student team, consisting of Lucy Chai, Elizabeth Kobe, Margaret Nolan, and Sushmitha Yarrabothula, picked up a project begun last year (a common practice with senior design projects) and demonstrated with their work that the imaging technique could be applied using a digital phantom (a computerized breast model) with great clarity, including successful resolution of a simulated mass just one-tenth of a millimeter in size.

Now, the four seniors will hand off the project to another team, continuing this multi-year research. Ultimately, before it can be applied in actual patients, the modality will need to be tested against the current standard of care in terms of its ability to detect small masses in the breast. Nevertheless, this year’s team moved the ball downfield significantly.